Table 1.
Comparison of clinical information in the training and validation sets
| Characteristics | Training cohort (n = 93) | Validation cohort (n = 40) | Training VS Validation P value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ALL cohort | Non pCR | pCR | P value | ALL cohort | Non pCR | pCR | P value | |||
| Age(year) | 51.51 ± 10.42 | 52.20 ± 10.32 | 49.56 ± 10.08 | 0.053 | 48.15 ± 12.08 | 48.28 ± 13.37 | 47.93 ± 10.00 | 0.931 | 0.107 | |
| Menstrual status | Premenopausal | 45 (48.39%) | 25 (42.37%) | 20 (58.82%) | 0.126 | 26 (65.00%) | 14 (56.00%) | 12 (80.00%) | 0.123 | 0.078 |
| Postmenopausal | 48 (51.61%) | 34 (57.63%) | 14 (41.14%) | 14 (35.00%) | 11 (44.00%) | 3 (20.00%) | ||||
| T stage | T1-2 | 69 (74.19%) | 41 (69.49%) | 28(82.35%) | 0.172 | 31 (77.50%) | 21 (84.00%) | 10 (66.67%) | 0.379 | 0.686 |
| T3-4 | 24 (25.81%) | 18 (30.15%) | 6 (17.65%) | 9 (22.50%) | 4 (16.00%) | 5 (33.33%) | ||||
| N stage | N1 | 21 (22.58%) | 14 (23.73%) | 7 (20.59%) | 0.727 | 14 (35.00%) | 6 (24.00%) | 8 (53.33%) | 0.06 | 0.136 |
| N0 | 72 (77.42%) | 45 (76.27%) | 27 (79.41%) | 26 (65.00%) | 19 (76.00%) | 7 (46.67%) | ||||
| BI-RAD stage | 4 | 5 (5.38%) | 1 (1.69%) | 4 (11.76%) | 0.024* | 5 (12.50%) | 3 (12.00%) | 2 (13.33%) | 0.9 | 0.214 |
| 5 | 58 (65.90%) | 41 (69.49%) | 17 (56.67%) | 19 (47.50%) | 11 (44.00%) | 8 (53.33%) | ||||
| 6 | 30(34.09%) | 17 (28.81%) | 13 (43.33%) | 16 (40.00%) | 11 (44.00%) | 5 (33.33%) | ||||
| ER status | Negative | 35 (37.63%) | 16 (27.12%) | 19 (55.88%) | 0.006* | 18 (45.00%) | 6 (24.00%) | 12 (80.00%) | 0.001* | 0.426 |
| Positive | 58 (62.37%) | 43 (72.88%) | 15 (44.12%) | 22 (55.00%) | 19 (76.00%) | 3 (20.00%) | ||||
| PR status | Negative | 39 (41.94%) | 19 (32.20%) | 20 (58.82%) | 0.012* | 19 (47.50%) | 7 (28.00%) | 12 (80.00%) | 0.001* | 0.553 |
| Positive | 54 (58.06%) | 40 (67.80%) | 14 (41.18%) | 21 (52.50%) | 18 (72.00%) | 3 (20.00%) | ||||
| HER2 status | Negative | 55 (59.14%) | 44(74.58%) | 11(32.35%) | < 0.001* | 24 (60.00%) | 18 (72.00%) | 6 (40.00%) | 0.046* | 0.926 |
| Positive | 38 (40.86%) | 15(25.42%) | 23(67.65%) | 16 (40.00%) | 7 (28.00%) | 9 (60.00%) | ||||
| Ki-67 status | Negative | 27 (29.03%) | 23 (38.98%) | 4 (11.76%) | 0.005* | 11 (27.50%) | 11 (44.00%) | 0 (0.00%) | 0.008* | 0.858 |
| Positive | 66 (70.97%) | 36 (61.02%) | 30 (88.24%) | 29 (72.50%) | 14 (56.00%) | 15 (100.00%) | ||||
| breast cancer subtypes | Luminal A | 10 (10.75%) | 10 (16.95%) | 0 (0.00%) | < 0.001* | 2 (5.00%) | 2 (8.00%) | 0 (0.00%) | 0.004* | 0.137 |
| Luminal B | 50 (53.76%) | 33 (55.93%) | 17 (50.00%) | 20 (50.00%) | 17 (68.00%) | 3 (20.00%) | ||||
| HER2 positive non luminal | 13 (13.98%) | 2 (3.39%) | 11 (32.35%) | 12 (30.00%) | 4 (16.00%) | 8 (53.33%) | ||||
| triple negative | 20 (21.51%) | 14 (23.73%) | 6 (17.65%) | 6 (15.00%) | 2 (8.00%) | 4 (26.67%) | ||||
*indicates statistical significant difference